Compare CRUS & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRUS | GKOS |
|---|---|---|
| Founded | 1984 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.9B |
| IPO Year | 1997 | 2015 |
| Metric | CRUS | GKOS |
|---|---|---|
| Price | $130.49 | $108.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $149.60 | $133.07 |
| AVG Volume (30 Days) | 588.8K | ★ 684.4K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.45 | N/A |
| EPS | ★ 6.27 | N/A |
| Revenue | ★ $1,896,077,000.00 | $507,442,000.00 |
| Revenue This Year | $6.11 | $23.39 |
| Revenue Next Year | $1.64 | $27.46 |
| P/E Ratio | $21.49 | ★ N/A |
| Revenue Growth | 5.99 | ★ 32.33 |
| 52 Week Low | $75.83 | $73.16 |
| 52 Week High | $146.88 | $130.23 |
| Indicator | CRUS | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 38.80 | 39.14 |
| Support Level | $114.49 | $104.72 |
| Resistance Level | $135.39 | $115.06 |
| Average True Range (ATR) | 4.38 | 4.81 |
| MACD | -1.94 | -0.91 |
| Stochastic Oscillator | 4.75 | 22.95 |
Cirrus Logic Inc is a provider of integrated circuits for audio and voice signal processing applications. The firm's products are organized into two streams: portable audio products, and HPMS Products. These products include aAmplifiers, codecs, smart codecs, analog-to-digital converters, digital-to-analog converters and standalone digital signal processors, Camera controllers, haptics and sensing solutions, and battery and power ICs. Roughly half of the firm's revenue is generated in China, with the rest coming from the United States, Europe, South Korea, and countries across the world.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.